Skip to main content

About

Aims and scope

Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:

Aging and development epigenetics

Allergy, immunology, and pathogen epigenetics

Cancer epigenetics and diagnostics

Cardiovascular epigenetics

Endocrinology and metabolic epigenetics

Environmental epigenetics

Epigenetic biomarkers

Epigenetic technologies

Epigenetic Drugs, Trials and Therapy

Innovative therapies

Lifestyle epigenetics

Neurology and psychiatry epigenetics

Regenerative medicine

Reproductive and transgenerational epigenetics

For more information on the the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here.

Editorial Policy on Submissions Involving RNAs

Differential RNA expression levels (coding or non-coding) or RNA modifications cannot be considered as part of epigenetics, and this includes levels of the RNA modifying enzymes or readers.

The fact that non-coding RNAs might affect other genes at their RNA level classifies these molecules as post-transcriptional gene expression regulators. Although modification of RNAs resembles modifications of DNA or histone proteins, so do post-translational modifications of various proteins. As such, RNAs modifiers as a class of regulators are not different from protein-modifiers, which also are not considered part of epigenetics per se

For manuscripts on non-coding RNAs to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:

  • data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes); or
  • insights on the mechanism of action of the non-coding RNA on the functioning of the DNA; or
  • insights in mitotic stability of the RNA-induced effect.

Editorial Policy Regarding Submissions Focusing on In silico research

Manuscripts reporting on straightforward bioinformatic analyses of publicly accessible databases only, cannot be considered for publication in Clinical Epigenetics, unless the manuscript presents:

  • new insights with well-described strong clinical impact and/or
  • additional insights into biological mechanisms (“wet-lab” validations) and/or
  • validations of findings in a replication cohort.

Open access

All articles published by Clinical Epigenetics are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

As authors of articles published in Clinical Epigenetics you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.

For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article processing charges (APC)

Authors who publish open access in Clinical Epigenetics are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.

The current APC, subject to VAT or local taxes where applicable, is: £2590.00/$3590.00/€2990.00

Visit our open access support portal and our Journal Pricing FAQs for further information.

Open access funding

Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.

Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.

Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.

Indexing services

All articles published in Clinical Epigenetics are included in:

  • Academic OneFile
  • CAS
  • DOAJ
  • Journal Citation Reports/Science Edition
  • OCLC
  • Medline
  • PubMed
  • PubMed Central
  • Science Citation Index Expanded
  • Scopus
  • Summon by Serial Solutions

The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.

Peer-review policy

Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.

Clinical Epigenetics operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.

The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.

Editorial policies

All manuscripts submitted to Clinical Epigenetics should adhere to BioMed Central's editorial policies.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Citing articles in Clinical Epigenetics

Articles in Clinical Epigenetics  should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Clin Epigenetics [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Clin Epigenetics 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Appeals and complaints

Authors who wish to appeal a rejection or make a complaint should follow the procedure outlined in the BMC Editorial Policies.

Benefits of publishing with BMC

High visibility

Clinical Epigenetics's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. 

Speed of publication

Clinical Epigenetics offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.

Flexibility

Online publication in Clinical Epigenetics gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Clinical Epigenetics are included in article alerts and regular email updates. Some may be highlighted on Clinical Epigenetics’s pages and on the BMC homepage.

In addition, articles published in Clinical Epigenetics may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Clinical Epigenetics. A list of articles recently press-released by journals published by BMC is available here.

Copyright

As an author of an article published in Clinical Epigenetics you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement).

For further information about the advantages of publishing in a journal from BMC, please click here.